How did Biocon disrupt the recombinant human insulin market in India?
Replied byKiran Mazumdar-Shaw
Founder & Executive Chairperson at Biocon
Niche: Health & Wellness
Revenue: Approx. $172 Million/month
Location: Bengaluru, Karnataka, India
Started: 1978
Recombinant human insulin was imported by Western multinationals who sold it at one thousand rupees per vial. We used a recombinant DNA technology based on Pichia yeast to produce human insulin domestically, dropping the price to one hundred rupees and forcing competitors to match us.
0
From the Full Interview
This answer is part of a full interview with Kiran Mazumdar-Shaw, Founder & Executive Chairperson at Biocon.
Share this Answer
Found this insight valuable? Share it with your network to help others learn from Kiran Mazumdar-Shaw's experience.
Cite This Answer
Use this answer in your research, article, or academic work
Related Answers
What challenges did you face when trying to enter the brewing industry in India?
By Kiran Mazumdar-Shaw
Health & Wellness
Approx. $172 Million/mo
Why did you choose to bypass the Indian market for your first GLP-1 drug launch?
By Kiran Mazumdar-Shaw
Health & Wellness
Approx. $172 Million/mo
Why did the market react skeptically to your acquisition of Viatris's biosimilar assets?
By Kiran Mazumdar-Shaw
Health & Wellness
Approx. $172 Million/mo
How has the ACA market evolved over the years?
By Mark Bertolin
Health & Wellness
$500M+/mo
How did your father's liberal worldviews shape your early career decisions?
By Kiran Mazumdar-Shaw
Health & Wellness
Approx. $172 Million/mo
What was your father's perspective on paying capitation fees to secure a college seat?
By Kiran Mazumdar-Shaw
Health & Wellness
Approx. $172 Million/mo
How did you make the transition from brewing to founding a biotechnology startup?
By Kiran Mazumdar-Shaw
Health & Wellness
Approx. $172 Million/mo